Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.890
-0.020 (-1.05%)
At close: Dec 5, 2025, 4:00 PM EST
1.880
-0.010 (-0.53%)
After-hours: Dec 5, 2025, 5:47 PM EST
Innate Pharma Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Innate Pharma stock ranges from a low of $2.00 to a high of $8.00. The average analyst price target of $5.00 forecasts a 164.55% increase in the stock price over the next year.
Price Target: $5.00 (+164.55%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 29, 2025.
Analyst Ratings
The average analyst rating for Innate Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $5 | Hold → Strong Buy | Upgrades | $5 | +164.55% | Oct 29, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +323.28% | Oct 29, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $10 → $2 | Buy → Hold | Downgrades | $10 → $2 | +5.82% | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Sep 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 → $11 | Strong Buy | Reiterates | $12 → $11 | +482.01% | Apr 24, 2025 |
Financial Forecast
Revenue This Year
24.61M
from 20.12M
Increased by 22.29%
Revenue Next Year
35.41M
from 24.61M
Increased by 43.90%
EPS This Year
-0.54
from -0.61
EPS Next Year
-0.50
from -0.54
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 78.8M | 68.3M | ||||
| Avg | 24.6M | 35.4M | ||||
| Low | 8.4M | 6.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 291.4% | 177.5% | ||||
| Avg | 22.3% | 43.9% | ||||
| Low | -58.4% | -75.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.45 | -0.43 | |
| Avg | -0.54 | -0.50 | |
| Low | -0.65 | -0.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.